Oncology

HR+/HER2- Early Breast Cancer

Advertisement

Expert Perspectives® in HR+/HER2- Early Breast Cancer to Cover Key Topics in HR+/HER2- Early Breast Cancer Treatment

expert perspectives by Ian Krop, MD, PhD; Melinda L. Telli, MD, FASCO
Overview

Expert Perspectives® delivers health care providers with insights from key thought leaders on the latest advancements and current practices in medicine, in a concise and timely format. Expert Perspectives® in HR+/HER2- Early Breast Cancer will feature community-selected experts and topics that we hope you will find of value in your clinical practice.


VIEW THE TOPICS:

 

Patient Care Perspectives

  • Multidisciplinary Management of Patients With Early-Stage HR+/HER2- Breast Cancer
  • Surveillance Expectations for Early-Stage Breast Cancer
  • Symptom Clusters That Matter to Patients With Early-Stage HR+/HER2- Breast Cancer

 

Clinical Topic Updates

  • Adjuvant CDK4/6 Inhibitors: Who Should Get Them and How to Manage Them
  • Multigene Assays and the Management of Early-Stage HR+/HER2- Breast Cancer
  • Risk Assessment and Reduction Strategies for Early-Stage HR+/HER2- Breast Cancer

 

Expert Roundtables

  • Expert Roundtable Podcast: Managing Endocrine Therapy-Related Side Effects and Adherence
  • Neoadjuvant Therapy for HR+/HER2- Breast Cancer

Ian Krop, MD, PhD

Professor of Internal Medicine, Section of Medical Oncology
Associate Cancer Center Director, Clinical Research
Chief Clinical Research Officer
Yale Cancer Center
Yale School of Medicine
New Haven, CT

Melinda L. Telli, MD, FASCO

Professor of Medicine, Division of Medical Oncology
Stanford University School of Medicine
Director, Breast Cancer Program
Associate Director of Clinical Research
Stanford Cancer Institute
Associate Director, Stanford Women's Cancer Center
Stanford, CA

Advertisement